文献速递肿瘤 PET/CT神经核医学核素与放射性配体治疗

初诊神经内分泌肿瘤患者中68Ga-DOTATATE与18F-FDG摄取异质性:哪些患者适合双示踪剂PET显像

Heterogeneous Uptake of 68 Ga-DOTATATE and 18 F-FDG in Initial Diagnosed Neuroendocrine Tumors Patients : Which Patients Are Suitable for Dual-Tracer PET Imaging?
PubMed 文献 · Clin Nucl Med · 2024-04-19

研究纳入51例初诊病理确诊神经内分泌肿瘤患者,于2020年1月至2022年9月行18F-FDG与68Ga-DOTATATE PET显像,分析双示踪剂摄取模式异质性、分期改变及预后价值。结果显示双示踪剂摄取模式与无进展生存期显著相关(单因素P=0.026,多因素P=0.039),而分级和分期与生存均不相关(均P>0.05)。作者结论认为双示踪剂PET显像可作为所有初诊神经内分泌肿瘤患者的预后工具。

要点

  • 双示踪剂摄取模式与无进展生存期显著相关(单因素P=0.026,多因素P=0.039)。
  • 分级和分期与生存均不相关(均P>0.05)。
  • 额外18F-FDG PET检出9例(17.6%)新病灶,其中3例(5.9%)临床分期改变。

核心结论

  • 本研究证实了初诊神经内分泌肿瘤的摄取异质性,并证明了双示踪剂PET显像的分期和预后价值。
  • 作者初步结果确认了双示踪剂显像模式的重要性,并结论认为双示踪剂PET显像可考虑作为所有初诊神经内分泌肿瘤患者的预后工具。

研究设计与样本

  • 纳入51例于2020年1月至2022年9月间接受18F-FDG和68Ga-DOTATATE PET显像的初诊病理确诊神经内分泌肿瘤患者。
  • 双示踪剂摄取模式分为3组:A组为68Ga-DOTATATE阳性且18F-FDG阴性,B组为68Ga-DOTATATE阳性且18F-FDG阳性,C组为68Ga-DOTATATE阴性且18F-FDG阳性。
  • 采用描述性统计分析不同分级组间、原发灶与转移灶间双示踪剂摄取模式的异质性及分期改变。
  • 采用Cox回归比较双示踪剂摄取模式、分级、年龄、性别和分期与无进展生存期的关系。

主要发现

  • 在不同分级组中,双示踪剂摄取模式A的患者均无3级组织学,但57%的1级患者具有FDG亲和性(其中25%导致双示踪剂摄取模式C)。
  • 无转移的患者均为高分化,但其中1例表现为双示踪剂摄取模式C。
  • 原发灶与转移灶间也观察到不同摄取模式,特别是44%原发灶为双示踪剂摄取模式A的患者其转移灶具有FDG亲和性。
  • 额外18F-FDG PET显像检出9例(17.6%)新病灶,其中3例(5.9%)临床分期相应改变。
  • Cox回归显示双示踪剂摄取模式与无进展生存期在单因素和多因素分析中均显著相关(P=0.026和0.039),而分级和分期与生存均不相关(均P>0.05)。

临床怎么用

  • 作者结论认为双示踪剂PET显像可考虑作为所有初诊神经内分泌肿瘤患者的预后工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study was designed to assess the uptake heterogeneity in neuroendocrine tumor (NET) patients at initial diagnosis with dual-tracer PET imaging and the staging changes and prognostic value it brings to explore the indication of the use of dual-tracer PET. METHODS: Fifty-one newly diagnosed patients with pathologically confirmed NET who underwent 18 F-FDG and 68 Ga-DOTATATE PET imaging between January 2020 and September 2022 were enrolled. Dual-tracer uptake patterns were classified into 3 groups: A. 68 Ga-DOTATATE positive and 18 F-FDG negative, B. 68 Ga-DOTATATE positive and 18 F-FDG positive, and C. 68 Ga-DOTATATE negative and 18 F-FDG positive. Descriptive statistics were used to evaluate the heterogeneity of dual-tracer uptake patterns among different grading (G) groups, between primary and metastatic lesions, and staging changes. Moreover, dual-tracer uptake patterns, grade, age, sex, and stage were compared with progression-free survival (PFS) by Cox regression. RESULTS: In the different G groups, none of the patients with dual-tracer uptake pattern A had grade 3 histology, but 57% of patients with grade 1 disease had FDG avidity (25% of them resulting in dual-tracer uptake pattern C). Patients with no metastasis were well differentiated, but one of them presented with dual-tracer uptake pattern C. Different uptake patterns were also observed between primary and metastatic lesions, particularly 44% of patients with dual-tracer uptake pattern A of primary with FDG avidity of metastases. Moreover, 9 (17.6%) had new lesions detected by additional 18 F-FDG PET imaging, and 3 of them (5.9%) had clinical stage changed accordingly. The Cox regression test showed that the dual-tracer uptake patterns were significantly correlated with PFS by univariate and multivariate analyses ( P = 0.026 and 0.039, respectively), whereas the grade and stage did not correlate with survival (all P >0.05). CONCLUSION: The current study has proven the uptake heterogeneity of the NET at initial diagnosis and demonstrated the staging and prognostic value of dual-tracer PET imaging. Our preliminary results have confirmed the importance of dual-tracer imaging modalities and concluded that dual-tracer PET imaging could be considered as prognostic tool for all patients with an initial diagnosis of NET.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zhou Y, Li L, Wang H, et al. Heterogeneous Uptake of 68 Ga-DOTATATE and 18 F-FDG in Initial Diagnosed Neuroendocrine Tumors Patients : Which Patients Are Suitable for Dual-Tracer PET Imaging? Clin Nucl Med. 2024. PMID: 38637950. doi:10.1097/RLU.0000000000005231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。